Clinical Trials for Corcept Therapeutics

Explore 10 clinical trials worldwide

Showing 1-10 of 10 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Corcept Therapeutics

Clinical Trials (10)

NCT06947304
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
PHASE1Recruiting
8 participants
Started: Aug 22, 2025 · Completed: Mar 31, 2026
4 conditions2 sponsors1 location
NCT06906341
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
PHASE2Recruiting
270 participants
Started: Apr 11, 2025 · Completed: Dec 31, 2026
4 conditions1 sponsor45 locations
NCT06829537
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
N/ARecruiting
1,000 participants
Started: Mar 28, 2025 · Completed: Dec 31, 2025
2 conditions1 sponsor46 locations
NCT06689254
REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism
PHASE2Recruiting
60 participants
Started: Nov 15, 2024 · Completed: Nov 15, 2026
1 condition2 sponsors1 location
NCT06108219
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
PHASE2Active, not recruiting
175 participants
Started: Oct 25, 2023 · Completed: Sep 30, 2026
2 conditions1 sponsor77 locations
NCT06099769
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
PHASE2Recruiting
201 participants
Started: Oct 18, 2023 · Completed: Oct 31, 2027
1 condition4 sponsors12 locations
NCT05407324
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
PHASE2Active, not recruiting
249 participants
Started: Nov 15, 2022 · Completed: May 31, 2027
1 condition1 sponsor35 locations
NCT05257408
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
PHASE3Active, not recruiting
381 participants
Started: Jun 29, 2022 · Completed: Mar 31, 2026
3 conditions2 sponsors117 locations
NCT03674814
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
PHASE1Active, not recruiting
35 participants
Started: Oct 23, 2018 · Completed: Mar 10, 2026
1 condition3 sponsors1 location
NCT03604198
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
PHASE2Active, not recruiting
125 participants
Started: May 7, 2018 · Completed: Dec 31, 2025
1 condition1 sponsor48 locations